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A B S T R A C T
Most men with advanced prostate cancer will develop bone metastases, which have a substantial impact on
quality of life. Bone metastases can lead to skeletal-related events (SREs), which place a burden on patients and
healthcare systems. For men with castration-resistant prostate cancer (CRPC) and bone metastases, the treatment
landscape has evolved rapidly over the past few years. The relatively recent approvals of the hormonal agents
abiraterone acetate and enzalutamide, second-line chemotherapy cabazitaxel, and the radiopharmaceutical ra-
dium-223 dichloride (radium-223), have provided clinicians with a greater choice of treatments. These com-
pounds have benefits in terms of overall survival based on the results of pivotal phase 3 studies. The bispho-
sphonate zoledronic acid and the RANK ligand inhibitor denosumab are indicated for the prevention of SREs in
men with metastatic CRPC but studies of these compounds have not demonstrated a survival benefit. The im-
portant question of the role of bisphosphonates or denosumab in combination with these new agents has thus
materialised. Current and emerging evidence from clinical studies of abiraterone acetate, enzalutamide and
radium-223, suggest that addition of bisphosphonates or denosumab to these new therapies may provide further
clinical benefits for patients with prostate cancer and bone metastases. This evidence may help to shape clinical
practice but are based largely on post hoc analyses of clinical trial data. It is therefore apparent that further data
are required from both clinical studies and real-world settings to enable physicians to understand the efficacy
and safety of combination therapy with the new agents plus bisphosphonates or denosumab.
Introduction
Since the approval of docetaxel in 2005 by the European Medicines
Agency (EMA) [1], the number of treatments extending the overall
survival (OS) of patients with metastatic castration-resistant prostate
cancer (mCRPC) has increased substantially. These treatments include
the chemotherapy cabazitaxel, the hormone therapies abiraterone
acetate (AA) and enzalutamide, and the radiopharmaceutical radium-
223 dichloride (radium-223) [2–5].
Prostate cancer preferentially metastasises to bone, with skeletal
metastases being present in up to 90% of patients with metastatic dis-
ease [6]. Metastatic bone disease appears early in the course of the
disease, so a substantial proportion of patients with cancer will develop
bone pain. Bone metastases also reduce the quality of life of patients
[7], Skeletal complications may occur and can require radiotherapy
and/or surgery. Skeletal complications are frequently aggregated into a
single clinical endpoint, skeletal-related events (SREs; pathologic frac-
ture, radiation or surgery to bone, and spinal cord compression). On
average, patients with bone metastatic mCRPC experience a SRE every
3–6months during their last year of life [8], placing a considerable
burden on the patients themselves and on healthcare systems. In ad-
dition, in patients with prostate cancer, the adjusted 1-year mortality
was 4.7-fold higher in those with bone metastases alone, and 6.6-fold
higher in those with bone metastases and SREs, compared with in-
dividuals with no metastases or SREs [9]. SREs may be indicative of
more advanced or aggressive disease, thus leading to increased mor-
tality. The term SREs includes asymptomatic fractures that are radi-
ologically detected but which have an unclear clinical relevance [10];
thus, some trials have used symptomatic-skeletal events (SSE) as a term
and composite endpoint when only referring to symptomatic events
(SSEs are defined as radiation to bone, symptomatic pathologic frac-
ture, surgery to bone or symptomatic spinal cord compression) [8].
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Inhibitors of bone resorption, such as the receptor activator of nu-
clear factor kappa B ligand (RANKL) inhibitor denosumab and the bi-
sphosphonate zoledronic acid (ZA), are approved for the prevention of
SREs in adults with advanced malignancies involving bone, including
prostate cancer [11,12].
There is some evidence that administering ZA in combination with
chemotherapy is beneficial in patients with mCRPC. In the phase 3
TRAPEZE (Taxotere® RadioisotoPE ZomEta®) study, the addition of ZA
to docetaxel therapy was found to have a beneficial effect on skeletal
morbidity compared with docetaxel alone, even though there was no
benefit in terms of OS [13]. However, there is now emerging evidence
from post hoc analyses of data from pivotal phase 3 studies that com-
bination therapy comprising bisphosphonates or denosumab plus AA or
enzalutamide or radium-223 may increase survival, as well as con-
ferring additional benefit in terms of preventing skeletal complications
in men with mCRPC [14–16]. Given the potential impact of SREs on
patients’ health, it is important to consider the role of new therapies
alongside bisphosphonates or denosumab to gain a better under-
standing of the potential involvement of combination therapy.
Pathophysiology of bone metastases in prostate cancer
Bone remodelling is a normal, dynamic process that is characterised
by osteoclast-mediated bone resorption followed by osteoblast-induced
bone formation. The process is closely regulated by a range of factors
including hormones, cytokines and growth factors [17–19].
Bone metastases can disrupt the bone remodelling process, leading
to a cycle of bone destruction [20,21]. The bone marrow micro-
environment may act as a reservoir for malignant cells and, once they
are within the bone microenvironment, prostate tumour cells have the
capacity to produce a wide range of cytokines and growth factors that
stimulate cells of osteoblastic lineage [21,22]. These, in turn, activate
osteoclasts, leading to increased bone resorption. Activated osteoclasts
can then release growth factors from the bone matrix that further sti-
mulate tumour growth and activity [20,21,23]. The increased osteo-
clast activity is not confined to metastatic sites, and can be more gen-
eralised [19].
Patients with metastatic prostate cancer commonly experience SREs
owing to increased osteolysis in typically osteoblastic bone lesions
[19,24]. On imaging, bone metastases in prostate cancer typically ap-
pear to be osteoblastic in nature, but there is thought to be a role for
osteoclasts too, with bone resorption thought to precede bone forma-
tion [19,20]. In preclinical models of prostate cancer, osteoclast in-
hibition prevents bone metastases [25,26]. Osteoclast activation
therefore plays a significant role in the development of metastases.
In addition, androgen deprivation therapy (ADT) can lead to cancer
treatment-induced bone loss (CTIBL), which increases bone resorption,
impairs bone stability and increases the risk of fractures in early-stage
prostate cancer, and can also increase the risk of SREs in patients with
metastatic prostate cancer [27,28].
Bisphosphonates or denosumab in men with castration-resistant
prostate cancer and bone metastases
Until recently, ZA and the RANKL inhibitor denosumab, which are
both indicated to prevent SREs in patients with advanced solid tumours
(Table 1) [11,12] were the only licensed agents available to reduce the
incidence of SREs in patients with prostate cancer. Table 2 summarises
the pivotal phase 3 studies of both the compounds and the new thera-
pies [11,12,29–42]. In a placebo-controlled study of 643 men with
mCRPC, fewer patients had at least one SRE following treatment with
intravenous ZA 4mg every 3 weeks versus placebo (38% vs 49% at
24months, p=0.028) [31]. ZA reduced the overall risk of skeletal
complications by 36% at 24months [31], and bone pain increased less
compared with placebo [29]. In a phase 3, placebo-controlled, double-
blind study of 1904 men with mCRPC, treatment every 4 weeks with Ta
bl
e
1
Su
m
m
ar
y
of
ke
y
ch
ar
ac
te
ri
st
ic
s
an
d
EU
in
di
ca
ti
on
s
fo
r
de
no
su
m
ab
,z
ol
ed
ro
ni
c
ac
id
,e
nz
al
ut
am
id
e,
ab
ir
at
er
on
e
ac
et
at
e
an
d
ra
di
um
-2
23
[3
–5
,1
1,
12
].
A
bi
ra
te
ro
ne
ac
et
at
e
En
za
lu
ta
m
id
e
R
ad
iu
m
-2
23
Zo
le
dr
on
ic
ac
id
D
en
os
um
ab
A
ge
nt
cl
as
s
H
or
m
on
e
th
er
ap
y
th
at
in
hi
bi
ts
17
α-
hy
dr
ox
yl
as
e/
C
17
,2
0-
ly
as
e
(C
Y
P1
7)
H
or
m
on
e
th
er
ap
y
th
at
in
hi
bi
ts
th
e
an
dr
og
en
re
ce
pt
or
α-
pa
rt
ic
le
em
it
te
r
Bi
sp
ho
sp
ho
na
te
H
um
an
m
on
oc
lo
na
la
nt
ib
od
y
ag
ai
ns
t
R
A
N
K
lig
an
d
D
os
in
g
fr
eq
ue
nc
y
10
00
m
g
or
al
ly
on
ce
da
ily
w
it
h
pr
ed
ni
so
ne
or
pr
ed
ni
so
lo
ne
10
m
g
on
ce
da
ily
16
0
m
g
or
al
ly
on
ce
da
ily
55
kB
q/
kg
IV
ev
er
y
4
w
ee
ks
4
m
g
IV
ev
er
y
3–
4
w
ee
ks
12
0
m
g
SC
ev
er
y
4
w
ee
ks
H
al
f-
lif
e
15
h
5.
8
da
ys
11
.4
da
ys
6
da
ys
28
da
ys
EU
ap
pr
ov
al
ye
ar
20
11
20
13
20
13
20
01
20
11
In
di
ca
ti
on
m
C
R
PC
in
m
en
w
ho
ar
e
as
ym
pt
om
at
ic
,
or
m
ild
ly
sy
m
pt
om
at
ic
,a
ft
er
fa
ilu
re
of
an
dr
og
en
de
pr
iv
at
io
n
th
er
ap
y
in
w
ho
m
ch
em
ot
he
ra
py
is
no
t
ye
t
cl
in
ic
al
ly
in
di
ca
te
d
or
in
th
os
e
w
ho
se
di
se
as
e
ha
s
pr
og
re
ss
ed
on
or
af
te
r
a
do
ce
ta
xe
l-b
as
ed
ch
em
ot
he
ra
py
re
gi
m
en
m
C
R
PC
in
m
en
w
ho
ar
e
as
ym
pt
om
at
ic
,
or
m
ild
ly
sy
m
pt
om
at
ic
,
af
te
r
fa
ilu
re
of
an
dr
og
en
de
pr
iv
at
io
n
th
er
ap
y
in
w
ho
m
ch
em
ot
he
ra
py
is
no
t
ye
t
cl
in
ic
al
ly
in
di
ca
te
d,
or
in
th
os
e
w
ho
se
di
se
as
e
ha
s
pr
og
re
ss
ed
on
or
af
te
r
a
do
ce
ta
xe
l-b
as
ed
ch
em
ot
he
ra
py
re
gi
m
en
m
en
w
it
h
C
R
PC
,s
ym
pt
om
at
ic
bo
ne
m
et
as
ta
se
s
an
d
no
kn
ow
n
vi
sc
er
al
m
et
as
ta
se
s
Pr
ev
en
ti
on
of
SR
Es
in
ad
ul
ts
w
it
h
ad
va
nc
ed
m
al
ig
na
nc
ie
s
in
vo
lv
in
g
bo
ne
Pr
ev
en
ti
on
of
SR
Es
in
ad
ul
ts
w
it
h
bo
ne
m
et
as
ta
se
s
fr
om
so
lid
tu
m
ou
rs
C
R
PC
,c
as
tr
at
io
n-
re
si
st
an
t
pr
os
ta
te
ca
nc
er
;E
U
,E
ur
op
ea
n
U
ni
on
;I
V
,i
nt
ra
ve
no
us
;m
C
R
PC
,m
et
as
ta
ti
c
C
R
PC
;r
ad
iu
m
-2
23
;
ra
di
um
-2
23
di
ch
lo
ri
de
;
SC
,s
ub
cu
ta
ne
ou
s;
SR
E,
sk
el
et
al
-r
el
at
ed
ev
en
t.
F. Saad et al. Cancer Treatment Reviews 68 (2018) 25–37
26
Ta
bl
e
2
Su
m
m
ar
y
of
pi
vo
ta
l
ph
as
e
3
st
ud
ie
s
of
de
no
su
m
ab
,z
ol
ed
ro
ni
c
ac
id
,e
nz
al
ut
am
id
e,
ab
ir
at
er
on
e
ac
et
at
e
an
d
ra
di
um
-2
23
,
sh
ow
in
g
st
ud
y
ch
ar
ac
te
ri
st
ic
s
an
d
ke
y
en
dp
oi
nt
s/
ou
tc
om
es
[1
4,
16
,2
9–
42
].
St
ud
y
D
ru
g
C
on
tr
ol
Pr
ofi
le
Pr
im
ar
y
en
dp
oi
nt
Se
co
nd
ar
y
en
dp
oi
nt
s
Sa
fe
ty
A
bi
ra
te
ro
ne
ac
et
at
e
C
O
U
-A
A
-3
02
[1
4,
36
]
A
bi
ra
te
ro
ne
(1
00
0
m
g/
da
y)
pl
us
pr
ed
ni
so
ne
(5
m
g
b.
d.
)
Pr
ed
ni
so
ne
(5
m
g
b.
d.
)
pl
us
pl
ac
eb
o
Ph
as
e
3,
ch
em
ot
he
ra
py
-
na
ïv
e
m
C
R
PC
;N
=
10
88
O
S:
34
.7
vs
30
.3
m
on
th
s;
H
R
:0
.8
1
(p
=
0.
00
33
)
Ti
m
e
to
de
cl
in
e
in
EC
O
G
PS
sc
or
e:
12
.3
vs
10
.9
m
on
th
s
(p
=
0.
00
5)
;t
im
e
to
in
it
ia
ti
on
of
cy
to
to
xi
c
ch
em
ot
he
ra
py
:2
5.
2
vs
16
.8
m
on
th
s
(p
<
0.
00
1)
;t
im
e
to
op
ia
te
us
e:
33
.4
vs
23
.4
m
on
th
s
(p
<
0.
00
01
)
A
Es
≥
gr
ad
e
3:
54
%
vs
44
%
C
O
U
-A
A
-3
01
[3
5,
38
]
A
bi
ra
te
ro
ne
(1
00
0
m
g/
da
y)
pl
us
pr
ed
ni
so
ne
(5
m
g
b.
d.
)
Pr
ed
ni
so
ne
(5
m
g
b.
d.
)
pl
us
pl
ac
eb
o
Ph
as
e
3,
m
C
R
PC
(p
re
vi
ou
s
do
ce
ta
xe
l)
;
N
=
11
95
(2
:1
ra
ti
o)
O
Sa
:1
5.
8
vs
11
.2
m
on
th
s;
H
R
:0
.7
4
(p
<
0.
00
01
)
TT
Pb
(P
SA
):
8.
5
vs
6.
6
m
on
th
s
(p
<
0.
00
1)
;
PF
Sb
:5
.6
vs
3.
6
m
on
th
s
(p
<
0.
00
1)
;P
SA
re
sp
on
se
b
:2
9%
vs
5.
5%
(p
<
0.
00
01
);
ti
m
e
to
fi
rs
t
SR
Ec
:2
5.
0
vs
20
.3
m
on
th
s
(p
=
0.
00
01
)
A
Es
≥
gr
ad
e
3
in
>
5%
of
pa
ti
en
ts
in
th
e
ab
ir
at
er
on
e
ar
m
b
:f
at
ig
ue
(9
.1
%
vs
10
.4
%
);
an
ae
m
ia
(7
.8
%
vs
8.
1%
);
ba
ck
pa
in
(7
.1
%
vs
10
.2
%
);
bo
ne
pa
in
(6
.4
%
vs
7.
6%
);
ar
th
ra
lg
ia
(5
%
vs
4%
)
En
za
lu
ta
m
id
e
A
FF
IR
M
[4
0,
41
]
En
za
lu
ta
m
id
e
(1
60
m
g/
da
y)
Pl
ac
eb
o
Ph
as
e
3;
C
R
PC
(p
re
vi
ou
s
do
ce
ta
xe
l)
;
N
=
11
99
O
S:
18
.4
vs
13
.6
m
on
th
s;
H
R
:0
.6
3
(p
<
0.
00
1)
Pr
op
or
ti
on
of
pa
ti
en
ts
w
it
h
≥
50
%
re
du
ct
io
n
in
PS
A
le
ve
l:
54
%
vs
2%
(p
<
0.
00
1)
;s
of
t-
ti
ss
ue
re
sp
on
se
ra
te
:2
9%
vs
4%
(p
<
0.
00
1)
;
qu
al
it
y
of
lif
e
re
sp
on
se
ra
te
:4
3%
vs
18
%
(p
<
0.
00
1)
;t
im
e
to
PS
A
pr
og
re
ss
io
n:
8.
3
vs
3.
0
m
on
th
s
(p
<
0.
00
1)
;r
ad
io
gr
ap
hi
c
PF
S:
8.
3
vs
2.
9
m
on
th
s
(p
<
0.
00
1)
;t
im
e
to
fi
rs
t
SR
E:
16
.7
vs
13
.3
m
on
th
s
(p
<
0.
00
1)
G
ra
de
≥
3
A
Es
in
>
5%
of
pa
ti
en
ts
in
th
e
en
za
lu
ta
m
id
e
ar
m
:f
at
ig
ue
(6
%
vs
7%
)
PR
EV
A
IL
[3
9,
42
]
En
za
lu
ta
m
id
e(
16
0
m
g/
da
y)
Pl
ac
eb
o
Ph
as
e
3;
ch
em
ot
he
ra
py
-
na
ïv
e
C
R
PC
;N
=
17
17
R
ad
io
gr
ap
hi
c
O
S
at
12
m
on
th
s:
65
%
vs
14
%
;H
R
:0
.1
9(
p
<
0.
00
1)
O
S:
32
.4
vs
30
.2
m
on
th
s;
H
R
:
0.
71
(p
<
0.
00
1)
Ti
m
e
to
ch
em
ot
he
ra
py
in
it
ia
ti
on
:2
8.
0
vs
10
.8
m
on
th
s
(p
<
0.
00
1)
;t
im
e
to
fi
rs
t
SR
E:
31
.1
vs
31
.3
m
on
th
s
(p
<
0.
00
1)
;t
im
e
to
PS
A
pr
og
re
ss
io
n:
11
.2
vs
2.
8
m
on
th
s
(p
<
0.
00
1)
G
ra
de
≥
3
A
Es
:4
3%
vs
37
%
R
ad
iu
m
-2
23
A
LS
Y
M
PC
A
[6
,1
6]
R
ad
iu
m
-2
23
(5
0
kB
q/
kg
qw
fo
r
si
x
in
je
ct
io
ns
)
Pl
ac
eb
o
Ph
as
e
3;
C
R
PC
w
it
h
bo
ne
m
et
as
ta
se
s;
N
=
92
1
(2
:1
)
O
S:
14
.9
vs
11
.3
m
on
th
s;
H
R
:
0.
70
(p
<
0.
00
1)
O
ve
ra
ll
ti
m
e
to
SR
E:
15
.6
vs
9.
8
m
on
th
s
(p
<
0.
00
37
)
ti
m
e
to
SR
E
(s
en
si
ti
vi
ty
an
al
ys
is
):
14
.7
vs
8.
1
m
on
th
s
(p
<
0.
00
01
);
ti
m
e
to
in
cr
ea
se
in
A
LP
le
ve
l:
7.
4
vs
3.
8
m
on
th
s
(p
<
0.
00
00
1)
:t
im
e
to
in
cr
ea
se
in
PS
A
le
ve
l:
3.
6
vs
3.
4
m
on
th
s
(p
<
0.
00
00
1)
G
ra
de
≥
3
A
Es
in
>
5%
of
pa
ti
en
ts
in
th
e
ra
di
um
-2
23
ar
m
:a
na
em
ia
(1
3%
vs
13
%
),
th
ro
m
bo
cy
to
pe
ni
a
(7
%
vs
2%
);
bo
ne
pa
in
(2
1%
vs
26
%
)
Zo
le
dr
on
ic
ac
id
Sa
ad
et
al
.[
29
]
Sa
ad
et
al
.[
31
]
Zo
le
dr
on
ic
ac
id
(4
m
g
q3
w
or
8
m
g
→
4
m
g
q3
w
)
Pl
ac
eb
o
Ph
as
e
3;
m
C
R
PC
;
N
=
64
3
SR
E
at
15
m
on
th
s
(z
ol
ed
ro
ni
c
ac
id
4
m
g
vs
zo
le
dr
on
ic
ac
id
8/
4
m
g
vs
pl
ac
eb
o)
:3
3.
2%
vs
38
.5
%
vs
44
.2
%
(p
=
0.
02
1
fo
r
zo
le
dr
on
ic
ac
id
4
m
g
vs
pl
ac
eb
o)
;
SR
E
at
24
m
on
th
s:
38
%
vs
41
%
vs
49
%
(p
=
0.
02
8
fo
r
zo
le
dr
on
ic
ac
id
4
m
g
vs
pl
ac
eb
o)
Ti
m
e
to
fi
rs
tS
R
E
at
24
m
on
th
s:
48
8
vs
36
3
vs
32
1
da
ys
;H
R
(z
ol
ed
ro
ni
c
ac
id
4
m
g
vs
pl
ac
eb
o)
:0
.6
8
(p
=
0.
00
9)
.
A
t
15
m
on
th
s
uN
Tx
re
du
ce
d
by
∼
70
%
w
it
h
zo
le
dr
on
ic
ac
id
(p
=
0.
00
1)
;p
ai
n
sc
or
es
in
cr
ea
se
d
m
or
e
w
it
h
pl
ac
eb
o
A
t
15
m
on
th
s,
re
na
l
fu
nc
ti
on
de
te
ri
or
at
io
n
du
ri
ng
in
fu
si
on
(1
5.
2%
vs
20
.7
%
vs
11
.5
%
);
gr
ad
e
3
cr
ea
ti
ni
ne
in
cr
ea
se
(3
.3
%
vs
2.
3%
vs
1.
0%
);
m
ya
lg
ia
(2
4.
8%
vs
24
.3
%
vs
17
.8
%
);
fe
ve
r
(2
0.
1%
vs
22
.0
%
vs
13
.0
%
)
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
F. Saad et al. Cancer Treatment Reviews 68 (2018) 25–37
27
Ta
bl
e
2
(c
on
tin
ue
d)
St
ud
y
D
ru
g
C
on
tr
ol
Pr
ofi
le
Pr
im
ar
y
en
dp
oi
nt
Se
co
nd
ar
y
en
dp
oi
nt
s
Sa
fe
ty
D
en
os
um
ab
Fi
za
zi
et
al
.[
30
]
Sm
it
h
et
al
.[
34
]
vo
n
M
oo
s
et
al
.
[3
2]
D
en
os
um
ab
(1
20
m
g
q4
w
)
pl
us
pl
ac
eb
o
Zo
le
dr
on
ic
ac
id
(4
m
g
q4
w
)
pl
us
pl
ac
eb
o
Ph
as
e
3;
bi
sp
ho
sp
ho
na
te
-
na
ïv
e
m
C
R
PC
;
N
=
19
04
In
te
gr
at
ed
an
al
ys
is
of
th
re
e
ph
as
e
3
st
ud
ie
s
in
so
lid
tu
m
ou
rs
;
N
=
55
44
Ti
m
e
to
fi
rs
t
SR
E:
20
.7
vs
17
.1
m
on
th
s;
H
R
:0
.8
2
(p
=
0.
00
02
,n
on
-i
nf
er
io
ri
ty
;
p
=
0.
00
8,
su
pe
ri
or
it
y)
Ti
m
e
to
fi
rs
t
an
d
su
bs
eq
ue
nt
SR
Es
:r
at
e
ra
ti
o
0.
82
(p
=
0.
00
8)
;u
N
Tx
re
du
ct
io
n:
84
%
vs
69
%
(p
<
0.
00
01
);
O
S:
19
.4
vs
19
.8
m
on
th
s;
TT
P:
8.
4
vs
8.
4
m
on
th
s;
ri
sk
of
de
ve
lo
pi
ng
fi
rs
t
SS
E:
H
R
0.
78
(p
=
0.
00
5)
;t
im
e
to
fi
rs
t
an
d
su
bs
eq
ue
nt
SS
Es
:
ra
te
ra
ti
o
0.
78
(p
=
0.
00
4)
;r
is
k
of
de
ve
lo
pi
ng
m
od
er
at
e-
to
-s
ev
er
e
pa
in
du
ri
ng
th
e
st
ud
y
fo
r
pa
ti
en
ts
w
it
h
a
fi
rs
t
on
-s
tu
dy
oc
cu
rr
en
ce
of
a
SS
E:
H
R
3.
07
,9
5%
C
I
2.
34
–4
.0
3
(p
<
0.
00
01
);
or
of
a
SR
E:
H
R
2.
09
,
95
%
C
I
1.
69
–2
.5
8
(p
<
0.
00
01
)
In
in
te
gr
at
ed
an
al
ys
is
of
th
re
e
ph
as
e
3
st
ud
ie
s
in
so
lid
tu
m
ou
rs
:
m
ed
ia
n
ti
m
e
un
ti
l
m
od
er
at
e-
to
-s
ev
er
e
pa
in
:m
ed
ia
n
6.
5
vs
4.
7
m
on
th
s,
H
R
,0
.8
3
(p
<
0.
00
1)
;r
el
at
iv
e
di
ff
er
en
ce
of
pa
ti
en
ts
pr
og
re
ss
in
g
fr
om
no
st
ro
ng
op
io
id
us
e
(A
Q
A
sc
or
e
0–
2)
to
st
ro
ng
op
io
id
us
e
(A
Q
A
sc
or
e
≥
3)
:–
13
.4
%
(p
=
0.
04
1)
G
ra
de
3/
4
A
Es
:7
2%
vs
66
%
(p
=
0.
01
);
hy
po
ca
lc
ae
m
ia
:(
13
%
vs
6%
;p
<
0.
00
01
);
O
N
J
(1
.8
%
vs
1.
3%
;
p
<
0.
09
);
ac
ut
e
ph
as
e
re
ac
ti
on
s
(8
%
vs
18
%
);
pe
r
pr
ot
oc
ol
do
se
ad
ju
st
m
en
ts
fo
r
re
na
l
im
pa
ir
m
en
t
(0
%
vs
22
%
);
pe
r
pr
ot
oc
ol
do
se
s
w
it
hh
el
d
ow
in
g
to
re
na
l
im
pa
ir
m
en
t
(0
%
vs
15
%
)
U
nl
es
s
ot
he
rw
is
e
sp
ec
ifi
ed
,a
ll
co
m
pa
ri
so
ns
in
di
ca
te
d
re
fe
r
to
dr
ug
ve
rs
us
co
nt
ro
l
gr
ou
ps
.I
f
th
er
e
is
no
p
va
lu
e
gi
ve
n
fo
r
a
co
m
pa
ri
so
n
th
e
di
ff
er
en
ce
in
va
lu
es
is
no
t
st
at
is
ti
ca
lly
si
gn
ifi
ca
nt
.
A
E,
ad
ve
rs
e
ev
en
t;
A
LP
,a
lk
al
in
e
ph
os
ph
at
as
e;
A
LS
Y
M
PC
A
,A
Lp
ha
ra
di
n
in
SY
M
Pt
om
at
ic
pr
os
ta
te
C
A
nc
er
pa
ti
en
ts
;A
Q
A
,A
na
lg
es
ic
Q
ua
nt
ifi
ca
ti
on
A
lg
or
it
hm
;b
.d
.,
tw
ic
e
da
ily
;C
R
PC
,c
as
tr
at
io
n-
re
si
st
an
t
pr
os
ta
te
ca
nc
er
;
EC
O
G
PS
,E
as
te
rn
C
oo
pe
ra
ti
ve
O
nc
ol
og
y
G
ro
up
pe
rf
or
m
an
ce
st
at
us
;H
R
,h
az
ar
d
ra
ti
o;
m
C
R
PC
,m
et
as
ta
ti
c
ca
st
ra
ti
on
-r
es
is
ta
nt
pr
os
ta
te
ca
nc
er
;N
R
,n
ot
re
ac
he
d;
O
N
J,
os
te
on
ec
ro
si
s
of
th
e
ja
w
;O
R
R
,o
bj
ec
ti
ve
re
sp
on
se
ra
te
as
pe
r
m
od
ifi
ed
re
sp
on
se
ev
al
ua
ti
on
cr
it
er
ia
in
so
lid
tu
m
ou
rs
;O
S,
ov
er
al
ls
ur
vi
va
l;
PF
S,
pr
og
re
ss
io
n-
fr
ee
su
rv
iv
al
;P
SA
,p
ro
st
at
e-
sp
ec
ifi
c
an
ti
ge
n;
q,
ev
er
y;
SR
E,
sk
el
et
al
-r
el
at
ed
ev
en
t;
SS
E,
sy
m
pt
om
at
ic
sk
el
et
al
ev
en
t;
TT
P,
ti
m
e
to
pr
og
re
ss
io
n;
uN
Tx
,u
ri
na
ry
N
-t
el
op
ep
ti
de
;w
,w
ee
ks
.
a
Fi
na
l
an
al
ys
is
.
b
In
te
ri
m
an
al
ys
is
.
c
Ex
pl
or
at
or
y
an
al
ys
is
.
F. Saad et al. Cancer Treatment Reviews 68 (2018) 25–37
28
subcutaneous denosumab 120mg was shown to be superior to in-
travenous ZA 4mg every 4 weeks for the time to first SRE, and to first
and subsequent SREs [30]. The time to first SRE was extended from
17.1 to 20.7months (hazard ratio [HR]: 0.82; 95% CI: 0.71–0.95;
p=0.008 for superiority). Denosumab significantly reduced the risk of
first and subsequent SREs by 18% compared with ZA (rate ratio: 0.82;
95% CI: 0.75–0.89; p=0.001 for superiority) [30]. Denosumab also
had a greater benefit in terms of slowing pain progression compared
with ZA. In patients with no-to-mild pain at baseline, denosumab sig-
nificantly increased the time until development of moderate-to-severe
pain compared with ZA (median: 6.5 vs 4.7months; HR: 0.83;
p < 0.001; 17% risk reduction), and fewer patients receiving deno-
sumab compared with ZA progressed to the use of strong opioids
(Table 2) [32]. OS (HR: 1.03; 95% CI: 0.91–1.17; p=0.65) and in-
vestigator-reported disease progression (HR: 1.06; 95% CI: 0.95–1.18;
p=0.30) were similar in the two treatment groups [30]. The beneficial
effect on SREs of denosumab relative to ZA was found regardless of
baseline characteristics, such as Eastern Cooperative Oncology Group
performance status (ECOG PS), number of bone metastases, presence or
absence of visceral metastases or urinary N-telopeptide level (a com-
monly used marker of bone turnover) [33]. A post hoc analysis of the
integrated study results has also shown that, compared with ZA, de-
nosumab reduced the frequency and significantly reduced the risk of
SSEs (p < 0.005; Table 2). Overall, similar beneficial effects of treat-
ment on bone pain were observed for SREs and SSEs (Table 2) [34].
New therapies combined with bisphosphonates or denosumab and
their effects on bone health in men with castration-resistant
prostate cancer and bone metastases.
New therapies have changed the face of mCRPC treatment, im-
proving survival and pain control, and having a positive effect on the
bone health of patients [6,35,36,41,42].
Abiraterone acetate
Oral AA 1000mg once daily was approved in the EU in 2011
(Table 1). It is indicated with prednisone or prednisolone 10mg once
daily for the treatment of mCRPC in men who are asymptomatic, or
mildly symptomatic, after failure of ADT in whom chemotherapy is not
yet clinically indicated, or in those whose disease has progressed on or
after a docetaxel-based chemotherapy regimen [5]. Two pivotal, pla-
cebo-controlled studies investigated AA plus prednisone (Table 2)
[35,36].
The concomitant use of bisphosphonates or denosumab was in-
vestigated in a post hoc analysis of the placebo-controlled COU-AA-302
study and provides clinical evidence regarding a possible beneficial
additive effect of these agents with AA in men with mCRPC [14]. In
COU-AA-302, AA plus prednisone therapy significantly increased the
median OS compared with prednisone alone in a cohort of 1088 che-
motherapy-naïve men with mCRPC who were asymptomatic or mildly
symptomatic (Table 2) [36]. Benefits of AA were also observed for pain
palliation but the effects on SRE occurrence were not investigated
[36,37]. A total of 353 patients (34% [184/546] of the AA group, 31%
[169/542] of the prednisone group) were receiving concomitant bi-
sphosphonates or denosumab. Of these 353 patients, 93% were treated
with ZA, 6% with denosumab and the remaining 1% with other bi-
sphosphonates. A total of 336 (95%) individuals were receiving bi-
sphosphonates or denosumab at baseline and another 17 (5%) com-
menced therapy with these agents during the study [14]. The baseline
characteristics of patients receiving or not receiving concomitant bi-
sphosphonates/denosumab were broadly similar across treatment
groups, except that a greater proportion of patients using bispho-
sphonates/denosumab had a Gleason score≥ 8 (57% vs 50%), bone
disease (93% vs 76%), and bone metastasis (55% vs 39%). Concomitant
use of bisphosphonates or denosumab was found to improve OS (Fig. 1)
compared with no use of these agents (HR: 0.75; 95% CI: 0.60–0.94;
p= 0.012), based on a median follow-up of 27.1 months. A longer time
to deterioration in ECOG PS (HR: 0.75; 95% CI: 0.64–0.87; p < 0.001)
and longer time to opiate use for cancer-related pain (HR: 0.80; 95% CI:
0.65–0.99; p=0.036) were also seen with concomitant use of bispho-
sphonates or denosumab compared with no use of these agents (Fig. 1)
[14].
Enzalutamide
Oral enzalutamide 160mg once daily was approved in the EU in
2013 (Table 1) [3]. Like AA, enzalutamide is indicated for the treatment
of mCRPC in men who are asymptomatic, or mildly symptomatic, after
Fig. 1. Kaplan–Meier plots of (a) overall survival, (b) time to opiate use for
cancer-related pain and (c) time to deterioration in ECOG PS score by≥1 point
for AA and concomitant bisphosphonates or denosumab use. Reproduced (with
permission) from Saad et al. [14]. AA, abiraterone acetate; BTA, bone-targeted
agent; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group
performance status; HR, hazard ratio; NE, not estimable; P, prednisone.
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failure of ADT in whom chemotherapy is not yet clinically indicated, or
in those whose disease has progressed on or after a docetaxel-based
chemotherapy regimen [3].
Two pivotal, placebo-controlled, phase 3 studies investigated en-
zalutamide in men with mCRPC, providing interesting findings re-
garding the effect of baseline bisphosphonate or denosumab use
[41,42]. The PREVAIL study of 1717 chemotherapy-naïve men with
mCRPC examined the effect of enzalutamide versus placebo on OS and
radiographic progression-free survival (rPFS) as the co-primary end-
points [42]. At baseline, approximately 17% of patients in both groups
had more than 20 bone metastases, and 26% of patients in the en-
zalutamide group and 27% in the placebo group were receiving bi-
sphosphonates or denosumab [43]. Beneficial effects on both OS and
rPFS were observed with enzalutamide, with a 29% reduction in the
risk of death compared with placebo (HR: 0.71; 95% CI: 0.60–0.84;
p < 0.001)[42]. Enzalutamide also reduced the median time to first
SRE (HR: 0.72; 95% CI: 0.61–0.84; p < 0.0001) and had benefits in
terms of pain progression compared with placebo [39].
Of note, the results of subgroup analyses indicated that en-
zalutamide provided numerically greater benefit in terms of rPFS than
placebo for patients who were not receiving bisphosphonates or deno-
sumab at baseline (HR: 0.16; 95% CI: 0.12–0.21) compared with those
who were (HR: 0.27; 95% CI: 0.18–0.41) (Fig. 2) [42]. However, it is of
note that the study was not designed or powered to test these interac-
tions nor analysed the effect on SREs for this subgroup. It is possible
that confounding factors (such as patient age and disease severity)
should be considered before concluding that concomitant bispho-
sphonates or denosumab may have a negative effect on SREs when
patients are treated with enzalutamide. Therefore, it may be useful to
physicians if a similar post hoc analysis, adjusted for confounding fac-
tors, was conducted in order to examine the effect of baseline con-
comitant use of bisphosphonates or denosumab on the time to devel-
opment of SREs in patients receiving enzalutamide, in addition to the
effect on rPFS or OS. Additional post hoc analyses of the PREVAIL study
have indicated that the benefit of enzalutamide on rPFS and OS could
be greater for patients with a low volume of bone disease (defined in
this analysis as< 4 bone metastases at screening) who may be less
likely to receive bisphosphonates or denosumab at this earlier disease
stage, versus a high volume of bone disease (≥4 bone metastases at
screening) [43]. However, the differences between these groups in OS
and rPFS were not formally statistically tested and so should be inter-
preted with caution [43].
In the AFFIRM study of 1199 men with mCRPC previously treated
with docetaxel, enzalutamide had a beneficial effect on OS, with a 37%
reduction in the risk of death compared with placebo (HR: 0.63; 95%
CI: 0.53–0.75; p < 0.001) (Fig. 2) [41]. At baseline, 43% of patients in
both groups were receiving bisphosphonates, and 38% had more than
20 bone metastases [40,41]. In a post hoc analysis, beneficial effects of
enzalutamide were also observed on SREs, health-related quality of life
and pain palliation [40]. The median time to first SRE in the en-
zalutamide group was 16.7 months compared with 13.3months in the
placebo group (HR: 0.69: 95% CI: 0.57–0.84; p=0.0001). This effect
was seen irrespective of bisphosphonate or corticosteroid use at base-
line [40].
Radium-223
Radium-223 was approved in the EU in 2013 (Table 1) and is in-
dicated for the treatment of men with mCRPC, symptomatic bone me-
tastases and no known visceral metastases [4]. The dose regimen of
radium-223 is an activity of 55 kBq per kg body weight, given at 4-week
intervals for six injections [4].
The effect of radium-223 on OS was investigated in the pivotal
phase 3, placebo-controlled ALpharadin in SYMPtomatic prostate
CAncer patients (ALSYMPCA) study of 921 men with CRPC and bone
metastases [6]. Patients were stratified at baseline based on ineligibility
or refusal to receive docetaxel chemotherapy. At baseline, approxi-
mately 40% of the patients were receiving bisphosphonates and ap-
proximately 30% had more than 20 bone metastases [6]. Treatment
with radium-223 led to a survival benefit compared with placebo
(median: 14.9 months vs 11.3 months; HR: 0.70; 95% CI: 0.58–0.83;
p < 0.001) [6]. Radium-223 significantly prolonged the time to an
increase in the total alkaline phosphatase (ALP) level (HR: 0.17; 95%
CI: 0.13–0.22; p < 0.001) [6], delayed the need for external-beam
radiation therapy [44] and improved patient health-related quality of
life versus placebo [45]. In a post hoc sensitivity analysis, the time to
first SSE was significantly longer with radium-223 (median
14.7 months) than with placebo (8.1 months; HR: 0.63; 95% CI:
0.50–0.79; p < 0.0001) [16].
The results of post hoc analyses from the ALSYMPCA study indicate
that bisphosphonates have a beneficial additive effect on bone health
when given in combination with radium-223 [16]. A greater benefit of
radium-223 over placebo on the time to first SSE was observed in pa-
tients who received bisphosphonates at baseline (HR: 0.49; 95% CI:
0.33–0.74; p= 0.00048) compared with those who did not (HR: 0.77;
95% CI: 0.58–1.02; p=0.07) (Fig. 3) [16]. Baseline use of bispho-
sphonates was associated with a decreased risk of SSEs in a multivariate
analysis (HR: 0.49; 95% CI: 0.38–0.64; p < 0.001) [16].
Findings from a prospective, phase 3b, early access programme of
radium-223 in 696 men with mCRPC have indicated that, in patients
receiving concomitant treatment with denosumab, there is a greater
beneficial effect on OS than in those not receiving concomitant deno-
sumab (Fig. 4) [46]. At baseline, 60% of patients had received previous
chemotherapy with docetaxel. Of those receiving concomitant therapy,
20% were treated with denosumab, 19% with bisphosphonates, 20%
with AA and 5% with enzalutamide [46]. In radium-223-treated pa-
tients, OS was longer in those treated concomitantly with denosumab
(median OS in months: NA [not available]; 95% CI: 15–NE [not es-
timable]) than in those who did not receive denosumab (median OS in
months: 13; 95% CI: 12–NE) [46]. In this study, benefits in terms of OS
with radium-223 treatment were observed in patients with a good
ECOG PS, no pain and low ALP levels [46]. The concomitant use of AA
or enzalutamide with radium-223 also had beneficial effects on OS in
this study; no effect of concomitant bisphosphonate use on OS was
observed [46].
Considerations for combination therapy for men with castration-
resistant prostate cancer and bone metastases
When considering a combination of therapies for men with CRPC
and bone metastases, the compounds selected should have differing
Fig. 2. The effect of enzalutamide treatment, stra-
tified by bisphosphonate use at baseline, on rPFS.
Reproduced (with permission) from Beer et al. [42].
CI, confidence interval; HR, hazard ratio; NYR, not
yet reached; rPFS, radiographic progression-free
survival.
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mechanisms of action and toxicity profiles [19]. Clinicians should also
consider the most appropriate dose, frequency and duration of treat-
ment and when to initiate specific regimens in order to optimise the use
of the new therapies [47]. As yet, there is insufficient prospective sci-
entific evidence to allow a full understanding of the optimal combina-
tion of new agents with bisphosphonates or denosumab, the optimal
time point at which to initiate treatment, or the optimum duration of
combination treatment.
Scientific rationale for combination therapy
The mechanisms of action of new therapies and of bisphosphonates
and denosumab are relatively well understood, and they appear to
target different aspects of the ‘vicious cycle’ of bone destruction asso-
ciated with metastatic prostate cancer (Fig. 5) [3–5,11,12]. This dif-
ferential targeting may provide a scientific rationale for the possible
additive effects on bone health thus far observed with combination
therapy.
Enzalutamide, AA and radium-223 primarily target the tumour cells
themselves. Despite treatment with medical or surgical castration, tu-
mour growth in men with CRPC can be driven by residual levels of
androgens, which may be synthesised by the tumour itself [5,48]. AA is
a hormone therapy that acts as a selective, potent and irreversible in-
hibitor of 17α-hydroxylase/C17,20-lyase (CYP17), which is required
for androgen biosynthesis. AA decreases serum testosterone to lower
levels than that achieved by ADT or orchiectomy by inhibiting CYP17 in
the testicular, adrenal and prostatic tumour tissues [5]. CYP17 inhibi-
tion by AA also results in increased mineralocorticoid production by the
adrenal glands. In early clinical studies this led to hypokalaemia, fluid
retention and hypertension; these events were largely abrogated by
coadministration of low-dose glucocorticoids, such as prednisone or
prednisolone [5,48,49].
Enzalutamide, another hormone therapy, blocks several steps in the
androgen receptor (AR) signalling pathway. It inhibits nuclear trans-
location of the AR, DNA binding and coactivator recruitment, even in
prostate cancer cells that are resistant to ADT [3,41]. Enzalutamide
decreases the growth of tumour cells, and can induce cancer cell death
and tumour regression [3].
Radium-223 is a radioisotope that has a completely different target
from enzalutamide or AA. Radium-223 mimics calcium and selectively
targets osteoblasts by forming complexes with the bone mineral hy-
droxyapatite, specifically in areas of high bone turnover, and emits α-
particles [4,6]. These α-particles are directly cytotoxic to the cells that
take them up (such as osteoblasts) by inducing double-strand DNA
breaks. Damage to the surrounding normal tissue is minimised owing to
the short range of the α-particles (< 10 cell diameters) [4,50,51].
Bisphosphonates and denosumab primarily target osteoclasts. Some
bisphosphonates, such as ZA, are nitrogen-containing compounds that
have a high affinity for mineralised bone. They selectively bind to bone
and inhibit farnesyl pyrophosphate synthase; this leads to inhibition of
osteoclast differentiation and survival and the stimulation of osteoblasts
[12,52]. Denosumab is a fully human monoclonal antibody that selec-
tively binds to RANKL, thereby preventing RANKL from activating its
receptor RANK on the surface of osteoclasts and their precursors
[11,30,53]. This inhibition by denosumab prevents the maturation of
osteoclasts and decreases bone resorption – breaking the ‘vicious cycle’
of bone destruction.
It is therefore feasible that, with a decrease in tumour burden or
activity within the bone microenvironment [38] following treatment
with new agents, there are fewer cytokines present or released from the
reduced number of tumour cells. Consequently, overall, there could be
less stimulation of osteoclasts and less bone resorption leading to less
bone destruction, which could result in lower levels of bone pain and a
longer time to SREs. The use of bisphosphonates or denosumab in
combination with new agents could possibly act in an additive manner
to maximise the benefits of the new agents, as shown by post hoc
findings of an additive effect on OS with concomitant use of denosumab
and radium-223 in the early access programme [46]. The additive ef-
fects of radium-223 with AA/enzalutamide also observed in the study
[46] suggest that further investigation is required to understand the
optimum combination of therapies fully in terms of patient benefit–risk.
In this regard, it is noteworthy that an increased incidence of death
(35% vs 28%) and fractures (26% vs 8%) was identified in asympto-
matic or mildly symptomatic patients with chemotherapy-naïve mCRPC
who received radium-223 in combination with abiraterone and pre-
dnisone/prednisolone compared with those receiving abiraterone plus
prednisone/prednisolone during a randomised phase 3 study assessing
SSEs [54]. The study was unblinded early as a result of the findings. The
EMA has advised physicians to not use this combination in patients with
mCRPC until full analysis of the study results is completed [55,56].
Although this hypothesis requires further testing, preclinical and
clinical data are beginning to emerge that describe an additional effect
of some new therapies on the bone microenvironment, which may offer
a rationale for the additive effects of combination therapy. In a recent
study conducted in vitro, and in vivo involving 49 patients with mCRPC,
AA was found to have a direct effect on bone anabolism and an anti-
resorptive effect, as shown by markers of bone turnover, namely an
increase in ALP levels and a decrease in serum carboxy-terminal col-
lagen crosslink values, respectively [57]. Based on the established
mechanisms of action of bisphosphonates and denosumab on the bone
microenvironment, it is feasible that there could be a potential additive
effect of AA on osteoclasts and osteoblasts in patients with prostate
Fig. 3. Post hoc effects of radium-223 on symptomatic skeletal events, stratified
by (a) bisphosphonate use and (b) no bisphosphonate use at ALSYMPCA study
entry. Reproduced (with permission) from Sartor et al. [16]. CI, confidence
interval; HR, hazard ratio; radium-223; radium-223 dichloride.
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cancer who have bone metastases [57] – in addition to the established
efficacy of AA on tumour burden – that could achieve better disease
control and management of bone health. Further evidence is required to
establish whether similar effects are observed with concomitant use of
radium-223 or enzalutamide with bisphosphonates or denosumab.
Safety considerations for combination therapy
In addition to mechanism of action, safety should be considered
when combining therapies with bisphosphonates or denosumab. The
safety profiles of all the concerned agents are well characterised and, on
the whole, are well tolerated by patients [3–5,11,12,41]. AA, en-
zalutamide, radium-223 and denosumab/ZA have non-overlapping
toxicities [3–5,11,12,41,52,58], thus reducing the possibility of serious
treatment-emergent adverse events from combination therapy [58].
There are, however, some safety issues of special interest that
should be appraised before any potential therapies are combined, and
the therapeutic choice may ultimately be driven by patient-specific
features (e.g. comorbidities and co-medication) [59]. Both ZA and de-
nosumab are generally well tolerated. Owing to their mechanism of
action, hypocalcaemia can occur when treatment is initiated [11,12]. It
‘stabilises’ thereafter and does not increase with a longer duration of
exposure [60]. Supplementation with calcium and vitamin D, pre-
treatment correction of low vitamin D and serum calcium levels, and
monitoring of serum calcium during treatment are required [11,12,61].
ZA is not recommended for patients with severe renal impairment
(creatinine clearance < 30mL/min) and dose adjustment may be re-
quired for patients with mild-to-moderate renal impairment [12]. De-
nosumab does not need renal dose reduction. However, individuals
with severe renal impairment are at risk of developing hypocalcaemia
Fig. 4. Kaplan–Meier curves showing overall survival with concomitant use of (a) novel endocrine agents and (b) denosumab in an early access, open-label phase 3b
study of radium-223. Reproduced (with permissions) from Saad et al. [46]. In this study, therapy was considered to be concomitant if a novel agent was started after
the first injection of radium-223 or if any such agent was administered before the provision of patient informed consent and continued after the first injection of
radium-223. CI, confidence interval; NA, not available; radium-223; radium-223 dichloride.
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and should be monitored closely [11].
There is a low, but notable, risk of osteonecrosis of the jaw (ONJ)
with ZA and denosumab treatment (1.3% and 1.8% in the comparative
study, respectively) [62]. The incidence of ONJ increases with time
[62], and recent long-term safety findings from the open-label exten-
sion phase of the comparative study showed a patient-year adjusted
incidence of confirmed ONJ of 1.1% during the first year of denosumab
treatment, 3.7% in the second year, and 4.6% per year thereafter
[63,64]. Of note, however, is the fact that a small increased risk of ONJ
in the oncology population has been associated with concomitant glu-
cocorticoid therapy [62,65–67]. This is of particular interest because
ONJ may emerge as a potential, albeit unlikely, problem with long-term
AA treatment, which is administered in combination with low-dose
prednisone [68]. However, an increase of ONJ associated with AA has
not been reported so far, although no specific attention for monitoring
ONJ was embedded in the COU-AA-301 or COU-AA-302 trials - in
contrast to the pivotal denosumab trials [62].
To reduce the risk of ONJ, the European Society for Medical
Oncology (ESMO) guidelines, among others, recommend preventative
dental measures before starting treatment, maintenance of good oral
hygiene and avoidance of invasive dental procedures during treatment
[69]. In the COU-AA-302 study of AA, there was an increased incidence
of ONJ with concomitant bisphosphonate or denosumab use compared
with no use of these agents. ONJ was reported in< 3% of patients
across the treatment groups; all cases were grade 1/2 [14]. A small risk
of ONJ was reported with radium-223, with an incidence of 0.6% re-
ported in the ALSYMPCA trial compared with no cases in the placebo
group; however, all four patients with ONJ were exposed to prior or
concomitant bisphosphonates [4]. The cumulative risk of ONJ would
therefore need to be considered when gauging the risk–benefit of
combining these therapies with bisphosphonates or denosumab.
Timing and additional considerations for combination therapy
In addition to the appropriate combination of therapies, the point at
which treatment with bisphosphonates or denosumab should be in-
itiated during the prostate cancer disease course has yet to be fully
determined. There is some evidence to suggest that there is better ef-
ficacy of ZA when initiated before the onset of bone pain [70]. How-
ever, some physicians wait until the newer hormonal agents have been
used and will initiate treatment with bisphosphonates or denosumab
only after symptomatic progression has been observed. Some physicians
may consider low-dose bisphosphonates or denosumab even before
bone metastases are present in order to reduce the risk of osteoporotic
fractures. For instance, for patients receiving therapies that may lead to
CTIBL (such as ADT), concomitant treatment with these antiresorptive
agents, at a lower dose than used in the metastatic setting, may be used
to prevent loss of bone [61,71].
As yet, guidelines do not provide recommendations on how to
combine bisphosphonates or denosumab with new agents [47,69,72].
The ESMO clinical practice guidelines on bone health in patients with
cancer state that antiresorptive agents should be commenced at the
time of diagnosis of metastatic bone disease in men with CRPC and
should continue indefinitely throughout the course of the disease [69].
Fig. 5. Mechanism of action of abiraterone acetate, enzalutamide, radium-223 dichloride, zoledronic acid and denosumab on osteoclasts/osteoblasts in the ‘vicious
cycle’ of bone destruction associated with metastasised prostate cancer.
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The combination of these agents with new therapies is not yet con-
sidered in these guidelines [69]. Guidelines from the St Gallen Ad-
vanced Prostate Cancer Consensus Conference for the management of
patients with mCRPC recommend that the majority of men with CRPC
with bone metastases should receive an osteoclast-targeted agent for
the prevention of SREs [47]. However, these guidelines report that the
optimal timing for starting such osteoclast-targeted treatment, optimal
treatment intensity (dose and frequency) and optimal treatment dura-
tion in men with CRPC is unclear [47].
Despite the lack of guidelines, evidence from real-world studies is
emerging regarding the concurrent use of bisphosphonates or deno-
sumab and new therapies [73]. Real-world treatment patterns of bi-
sphosphonates or denosumab use across six EU countries have indicated
that 74% (n=1454) of 1971 patients with advanced prostate cancer
and bone metastases were receiving one of these agents. A large pro-
portion of patients given a novel therapy were receiving concurrent
treatment with bisphosphonates or denosumab: 75% (n=335/449) of
patients receiving AA, 67% (n= 99/148) of those receiving en-
zalutamide and 70% (n=7/10) of those receiving radium-223 [73].
Ongoing clinical studies investigating combinations of new agents
are likely to provide additional useful information for physicians con-
sidering optimal treatments for patients (Table 3). The ongoing phase 3,
double-blind, placebo-controlled ERA 223 study (ClinicalTrials.gov
identifier: NCT02043678) is researching the combination of radium-
223 and AA with prednisone/prednisolone in the treatment of ap-
proximately 800 asymptomatic or mildly symptomatic chemotherapy-
naïve men with bone-predominant mCRPC. SSE-free survival is the
primary endpoint and patients will be stratified by with or without
concurrent use of denosumab or bisphosphonates [74]. As mentioned
earlier in this review, the ERA 223 trial was unblinded early due to an
imbalance in the incidence of deaths and fractures in patients who re-
ceived radium-223 combination therapy [54–56]. The phase 3
PEACE III study (ClinicalTrials.gov identifier: NCT02194842) may help
to understand if there is a beneficial effect of using a bone-targeted
agent with radium-233 [75]. In this study, comparing radium-233 plus
enzalutamide with enzalutamide alone in asymptomatic or mildly
symptomatic mCRPC, the use of a bone-targeted agent to reduce the
risk of fractures and other SREs is recommended in all patients entering
the study. Finally, a small study (ClinicalTrials.gov identifier:
NCT02758132) is recruiting patients to investigate the combination of
denosumab plus enzalutamide, AA and prednisone, versus denosumab
plus enzalutamide, in men with mCRPC to characterise serum meta-
bolites associated with bone deposition, growth and turnover.
This review focuses on men with CRPC and bone metastases.
However, data are lacking on the use of new agents in combination with
bisphosphonates or denosumab in patients with hormone sensitive
prostate cancer (HSPC). A randomised controlled trial investigating the
use of ZA in men receiving ADT for HSPC (CALGB 90202) found no
significant benefits from the use of the bisphosphonate in terms of time
to first SRE or OS [76]. Results of the multistage, open-label, rando-
mised controlled Systemic Therapy in Advancing or Metastatic Prostate
cancer: Evaluation of Drug Efficacy (STAMPEDE) study have indicated
that, although well-tolerated, the addition of ZA to ADT in men with
HSPC conferred no survival benefit, and no decrease in SREs; by con-
trast, the addition of docetaxel to ADT was beneficial in terms of OS and
in preventing SREs [77]. The lack of evidence for using bispho-
sphonates in HSPC could reflect the low rate of SREs in this setting, and
the consequent challenges with obtaining sufficient data to show an
effect.
More recently, the STAMPEDE authors reported clinically and sta-
tistically significant improvements in OS and failure-free survival in
men with HSPC receiving AA and prednisolone in addition to ADT
(compared to ADT alone, with a manageable increase in toxicity [78]. A
significant increase in the proportion of patients without SSEs over a 3-
year period was reported for the AA plus ADT arm, versus the ADT
alone arm [78]. The number of grade 3–5 events was, however, higher
in the combination arm (47% vs 33%). The results from the first interim
analysis of the LATITUDE trial of AA and prednisone added to ADT in
men with newly diagnosed high-risk metastatic HSPC reported sig-
nificant improvements in men randomised to add-on AA (vs placebo) in
terms of OS, rPFS and all secondary endpoints, including time to next
SSE. Despite an increase in Grade 3/4 adverse events (hypertension,
hypokalemia, increased ALT or AST) in the add-on AA (vs placebo)
treatment arm, the ethics committee have recommended unblinding
and crossing all placebo/ADT patients over to AA/ADT [79].
Future perspectives
In conclusion, the addition of bisphosphonates or denosumab to
new therapies has the potential to provide clinical benefits for men with
prostate cancer and bone metastases and there is evidence of an ad-
ditive effect between these agents and the new therapies. However, this
is based largely on post hoc data from clinical trials, which have lim-
itations. Further evidence is therefore required from clinical studies and
the real-world setting to enable physicians to understand the efficacy
and safety of combination therapy with new agents and bispho-
sphonates or denosumab. Given the current evidence gaps, a rando-
mised study to demonstrate prospectively the benefits of combining
new therapies with these inhibitors of bone resorption could be de-
signed on the basis of currently available data in order to inform clin-
icians further.
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